Please click here to read a statement from Amicus Therapeutics regarding COVID-19.

Announcement Regarding COVID-19 and the Pull for Pompe (03/18/2020): After careful consideration, and long discussions among the organizers; the 2020

AMDA WEBINAR Title:  The common c.-32-13T>G splicingA normal step in how the body reads gene instructions. If splicing goes wrong, the wrong protein may... More variant of GAA geneThe gene responsible for making the GAA enzyme. More: from functional characterization to the identification of new therapeutic

On October 25-27, 2019, almost 200 Pompe patients and their families, scientists, doctors, and industry representatives from around the world

The AMDA is excited to announce that it is partnering with the MDA to host a Patient Focused Drug Development

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This

The AMDA/IPA International Pompe Patient and Scientific Conference will take place in San Antonio, Texas from October 25-27, 2019. Please

The AMDA is excited to announce that the 2019 PCMA’s Pull for Pompe will take place on Saturday, April 13th

Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More Global